INNOVIVA, INC. Deferred Income Tax Expense (Benefit)
INNOVIVA, INC. (INVA) reported Deferred Income Tax Expense (Benefit) of $4.95 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-05
- INNOVIVA, INC. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was -$36.09M.
- INNOVIVA, INC. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was $41.04M.
- INNOVIVA, INC. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was $39.77M, a 1309.96% increase year-over-year.
- INNOVIVA, INC. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was $4.95M.
- INNOVIVA, INC. deferred income tax expense (benefit) for fiscal 2025 was $43.85M.
- INNOVIVA, INC. deferred income tax expense (benefit) for fiscal 2024 was -$12.62M, a 386.75% decline from fiscal 2023.
- INNOVIVA, INC. deferred income tax expense (benefit) for fiscal 2023 was $4.40M, a 82.40% decline from fiscal 2022.
- INNOVIVA, INC. deferred income tax expense (benefit) for fiscal 2022 was $25.01M, a 67.28% decline from fiscal 2021.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$36.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.95M 10-Q · filed 2026-08-05 | $44.72M derived: sum of 3 quarters · filed 2026-08-05 | $49.67M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $41.04M 10-Q · filed 2026-05-06 | $80.81M derived: sum of 2 quarters · filed 2026-05-06 | $85.76M derived: sum of 3 quarters · filed 2026-05-06 | $85.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $39.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $44.72M derived: sum of 2 quarters · filed 2026-02-25 | $44.09M derived: sum of 3 quarters · filed 2026-08-05 | $43.85M 10-K · filed 2026-02-25 |
| 2025-09-30 | $4.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.31M derived: sum of 2 quarters · filed 2026-08-05 | $4.07M 10-Q · filed 2025-11-05 | $6.89M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$637.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$877.00K 10-Q · filed 2026-08-05 | $1.94M derived: sum of 3 quarters · filed 2026-08-05 | -$1.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$240.00K 10-Q · filed 2026-05-06 | $2.58M derived: sum of 2 quarters · filed 2026-05-06 | -$848.00K derived: sum of 3 quarters · filed 2026-05-06 | -$16.10M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $2.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$608.00K derived: sum of 2 quarters · filed 2026-02-25 | -$15.86M derived: sum of 3 quarters · filed 2026-02-25 | -$12.62M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$3.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$18.68M derived: sum of 2 quarters · filed 2025-11-05 | -$15.44M 10-Q · filed 2025-11-05 | -$9.92M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$15.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$12.01M 10-Q · filed 2025-08-06 | -$6.49M derived: sum of 3 quarters · filed 2026-02-25 | -$8.14M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $3.24M 10-Q · filed 2025-05-07 | $8.76M derived: sum of 2 quarters · filed 2026-02-25 | $7.11M derived: sum of 3 quarters · filed 2026-02-25 | $8.46M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $5.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $3.87M derived: sum of 2 quarters · filed 2026-02-25 | $5.21M derived: sum of 3 quarters · filed 2026-02-25 | $4.40M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$303.00K derived: sum of 2 quarters · filed 2024-11-06 | -$1.11M 10-Q · filed 2024-11-06 | -$5.37M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $533.00K 10-Q · filed 2024-07-31 | -$3.72M derived: sum of 3 quarters · filed 2025-02-26 | $19.55M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | -$812.00K 10-Q · filed 2024-05-08 | -$5.06M derived: sum of 2 quarters · filed 2025-02-26 | $18.21M derived: sum of 3 quarters · filed 2025-02-26 | $17.33M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | -$4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $19.02M derived: sum of 2 quarters · filed 2025-02-26 | $18.15M derived: sum of 3 quarters · filed 2025-02-26 | $25.01M 10-K · filed 2025-02-26 |
| 2022-09-30 | $23.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $22.40M derived: sum of 2 quarters · filed 2023-11-01 | $29.26M 10-Q · filed 2023-11-01 | $40.09M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | -$876.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $5.98M 10-Q · filed 2023-08-02 | $16.82M derived: sum of 3 quarters · filed 2024-03-05 | $37.35M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $6.86M 10-Q · filed 2023-05-09 | $17.69M derived: sum of 2 quarters · filed 2024-03-05 | $38.22M derived: sum of 3 quarters · filed 2024-03-05 | $63.56M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $10.83M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | $31.36M derived: sum of 2 quarters · filed 2024-03-05 | $56.70M derived: sum of 3 quarters · filed 2024-03-05 | $76.43M 10-K/A · filed 2024-03-05 |
| 2021-09-30 | $20.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $45.86M derived: sum of 2 quarters · filed 2022-11-09 | $65.60M 10-Q · filed 2022-11-09 | $81.33M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $25.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $45.07M 10-Q · filed 2022-07-27 | $60.80M derived: sum of 3 quarters · filed 2023-02-28 | $69.67M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $19.74M 10-Q · filed 2022-05-05 | $35.47M derived: sum of 2 quarters · filed 2023-02-28 | $44.33M derived: sum of 3 quarters · filed 2023-02-28 | $64.22M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $15.73M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $24.60M derived: sum of 2 quarters · filed 2023-02-28 | $44.49M derived: sum of 3 quarters · filed 2023-02-28 | $60.42M 10-K · filed 2023-02-28 |
| 2020-09-30 | $8.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $28.76M derived: sum of 2 quarters · filed 2021-10-27 | $44.69M 10-Q · filed 2021-10-27 | $57.06M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-06-30 | $19.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $35.82M 10-Q · filed 2021-07-29 | $48.20M derived: sum of 3 quarters · filed 2022-03-17 | $58.76M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-03-31 | $15.93M 10-Q · filed 2021-04-28 | $28.31M derived: sum of 2 quarters · filed 2022-03-17 | $38.87M derived: sum of 3 quarters · filed 2022-03-17 | $49.30M derived: sum of 4 quarters · filed 2022-03-17 |
| 2019-12-31 | $12.38M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-17 | $22.93M derived: sum of 2 quarters · filed 2022-03-17 | $33.37M derived: sum of 3 quarters · filed 2022-03-17 | $41.88M 10-K/A · filed 2022-03-17 |
| 2019-09-30 | $10.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $20.99M derived: sum of 2 quarters · filed 2020-10-28 | $29.50M 10-Q · filed 2020-10-28 | -$166.56M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $10.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $18.94M 10-Q · filed 2020-07-29 | -$177.11M derived: sum of 3 quarters · filed 2021-02-25 | -$177.11M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $8.51M 10-Q · filed 2020-04-29 | -$187.55M derived: sum of 2 quarters · filed 2021-02-25 | -$187.55M derived: sum of 3 quarters · filed 2021-02-25 | -$187.55M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$196.05M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$196.05M derived: sum of 2 quarters · filed 2021-02-25 | -$196.05M derived: sum of 3 quarters · filed 2021-02-25 | -$196.05M 10-K · filed 2021-02-25 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $0.00 derived: sum of 2 quarters · filed 2019-10-30 | $0.00 10-Q · filed 2019-10-30 | |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | $0.00 10-Q · filed 2019-07-24 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-01 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-19 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |